Benzinga’s Top Pre-Market NASDAQ Losers (IMGN, OVTI, NOVL, ARMH)

ImmunoGen Inc IMGN dipped 23.12% to $6.45 in the pre-market session. IMGN has received a Refuse to File (RTF) letter from the FDA for its breast cancer treatment. OmniVision Technologies Inc OVTI lost 2.85% to $21.50 in the pre-market session. OVTI had reported weaker-than-expected Q1 revenue. Novell Inc NOVL fell 2.30% to $5.51 in the pre-market session. NOVL had posted weaker-than-expected FQ3 results. ARM Holdings Plc ARMH slipped 0.91% to $15.29 in pre-market trading. ARMH’s earnings are likely to fall by 8.26% this year. Read more from Benzinga's Company news.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsFDAPre-Market OutlookIntraday UpdateMarketsTrading IdeasBiotechnologyHealth CareInformation TechnologySemiconductorsSystems SoftwareTop Pre-Market NASDAQ Losers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!